immunos - ImmunOs Therapeutics team has extensive expertise duck 88 slot in the field of drug development and global commercialization in immunology immunotherapy and oncology The Companys mission is to develop the next generation of novel immunotherapeutics that will improve the lives of patients with serious diseases ImmunOs Therapeutics AG Raises 11 Million and Further Our Company Immunostherapy May 24 2023 ImmunOs lead program is a multifunctional fusion protein that blocks specific LILRB leukocyte immunoglobulinlike and KIR killer cell immunoglobulinlike receptors and activates antitumor Jun 7 2022 The proceeds of the Series B will be used to fund the clinical development of ImmunOs lead program IOS1002 formerly iosH2 through Phase 2 clinical trials and to progress additional Sep 17 2024 ImmunOs Therapeutics AG a biopharmaceutical company leveraging its unique immune system modulating HLAbased technology platform to develop firstinclass therapeutics for the treatment of cancer and autoimmune diseases today announced the closing of a Series C financing round of 11 million The round was led by existing investors Gimv Pfizer Ventures Mission BioCapital BioMed Partners Nov 15 2022 ImmunOs lead program is a multifunctional fusion protein that blocks specific LILRB leukocyte immunoglobulinlike and KIR killer cell immunoglobulinlike receptors and activates antitumor What Is Immunotherapy Cancer Research Institute Jun 7 2022 ImmunOs lead program is a multifunctional fusion protein that blocks specific LILRB leukocyte immunoglobulinlike and KIR killer cell immunoglobulinlike receptors and activates antitumor Management Team Immunostherapy ImmunOs is a Swiss company that develops novel immunotherapies based on human leukocyte antigen HLA molecules It aims to activate the immune system of cancer patients and block the activation of HLA molecules in autoimmune diseases ImmunOs approach is based on the identification of specific human leukocyte antigen HLA molecules that hyperactivate the immune system of patients with severe autoimmune disorders The company has utilized this discovery to develop an HLAbased technology platform to generate a novel class of biologic therapeutics for the treatment of HLABased Technology Platform Immunostherapy Nov 15 2022 November 15 2022 ImmunOs Therapeutics AG a biopharmaceutical company leveraging its HLAbased technology platform to develop firstinclass therapeutics for the treatment of cancer and ImmunOs Therapeutics Raises 74 Million Series B Financing Round Sep 17 2024 Existing investors and new investor Double Point Ventures join forces to support ImmunOs TherapeuticsInvestment secures funding of ongoing promising clinical trial of IOS1002 in solid cancers ImmunOs Therapeutics Lead Program Shows Strong AntiTumor ImmunOs has developed a proprietary human leukocyte antigen HLAbased platform to generate a novel class of biologic therapeutics for the treatment stacatto of cancer and autoimmune disease These novel therapies target both the adaptive and innate immune systems including myeloidderived cells T cells and NK cells ImmunOs Therapeutics Lead Program Shows Strong AntiTumor ImmunOs Therapeutics Crunchbase Company Profile Funding ImmunOs Therapeutics Announces Initiation of Dosing in Phase Sep 17 2024 ImmunOs lead program is a multifunctional HLAfusion protein that binds specific LILRB leukocyte immunoglobulinlike and KIR killer cell immunoglobulinlike receptors and can stimulate both the innate and the adaptive immune systems of cancer patients to eliminate tumor cells ImmunOs Therapeutics is a clinicalstage biotechnology company ImmunOs Therapeutics AG is a clinicalstage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunityTheir mission is to develop the next generation of novel therapeutics that will improve the lives of patients with ImmunOs Therapeutics Raises 74 Million Series B Financing ImmunOs has established a comprehensive data set of validated results with a global team of scientific and commercial immunotherapy immunology and oncology experts In preclinical studies therapeutic efficacy of the Companys lead program IOS1002 has been demonstrated as monotherapy and in combination with standardofcare cancer therapies ImmunOs Therapeutics Announces Clinical Trial Collaboration What is immunotherapy Cancer immunotherapy also known as immunooncology is a form of cancer treatment that uses the power of the bodys own immune system to prevent control and eliminate cancer ImmunOs Therapeutics Lead Program Shows Strong AntiTumor Oct 17 2023 ImmunOs is currently enrolling patients in the Phase 1ab trial initiated earlier this year to evaluate the potential of IOS1002 as a monotherapy and in combination with KEYTRUDA in adult ENGAGING THE ENTIRE IMMUNE SYSTEM TO FIGHT DISEASE ImmunOs Therapeutics AG LinkedIn ImmunOs Therapeutics AG is a biotech company that develops novel immunomodulatory proteins for cancer and autoimmune diseases The company has a lead program iosH2 that targets LILRB receptors and enhances antitumor responses in combination with checkpoint inhibitors Nov 15 2021 November 15 2021 ImmunOs Therapeutics AG a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases today announced promising ImmunOs Therapeutics AG Raises 11 Million and Further ImmunOs develops firstinclass immunotherapies that engage both the innate and the adaptive immune systems Its lead product candidate IOS1002 blocks multiple immunosuppressive receptors and has the potential to treat multiple types of solid tumors and hematologic malignancies The Next Generation Pipeline Immunostherapy Approach Immunostherapy ImmunOs Therapeutics raises USD bistik ayam 11 million and strengthens
izmi
reh
